>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance:

  • BTI -1.1%, (provides H1 trading update)

Select metals/mining stocks trading lower:

  • GFI -1.3%, BHP -1%, BBL -0.9%, MT -0.7%, GOLD -0.7%, GDX -0.6%

Other news:

  • IDRA -14.5% (announces results from the Phase 2 clinical trial of IMO-8400 in adult patients with dermatomyositis)
  • IMMU -4.3% (commenced an underwritten public offering of $275,000,000 of shares of its common stock)
  • HTGC -3.4% (commences 6 mln common stock offering)
  • MEDP -2.6% (prices secondary offering of 3 mln shares of its common stock by selling shareholders at $42.25 per share)
  • HCC -1.7% (secondary offering of 4 mln shares of common stock by selling shareholders)
  • HOME -1.6% (secondary offering of 8.0 mln shares of common stock)
  • FBC -0.5% (prices secondary offering of 8 mln shares of common stock at $34.50 per share)

Analyst comments:

  • SEAS -8.6% (downgraded to Sell from Neutral at Citigroup)
  • BPL -2.8% (downgraded to Neutral from Buy at UBS)
  • TRGP -1.3% (downgraded to Equal Weight from Overweight at Barclays)
  • BF.B -1.2% (downgraded to Sell from Hold at Societe Generale)
  • ABX -1.1% (downgraded to Underweight from Equal-Weight at Morgan Stanley)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

  • RH +20.9%, PLAY +13.8%, LE +10.6%, KMG +5.9%, URBN +3.8%, (discloses that thus far during the Q2, comparable Retail segment net sales are mid teens positive)

M&A news:

  • QCP +1.2% (announces receipt of acquisition proposal that could reasonably be expected to lead to a 'Superior Offer')
  • SGH +1.1% (acquires Penguin Computing for up to $85 million, which includes up to $25 million of performance-based payments)

Other news:

  • GLMD +221.4% (announces top-line, 52-week results from the global Phase 2b ARREST study, says data strongly support advancement of Aramchol 600mg to Phase 3)
  • BLDP +12.2% (signs 3.5-Year extension to long-term program for fuel cell passenger cars with AUDI AG)
  • PSTI +8.6% (positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication)
  • TNDM +4.2% (Deerfield Mgmt discloses 5.54% passive stake)
  • SAGE +4% (announces expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the FDA)
  • PFNX +2.6% (Pfenex and Alvogen enter into agreement granting Alvogen exclusive rights to commercialize Pfenex's lead drug candidate, PF708)
  • I +1.5% (prices concurrent offerings of common shares and convertible notes)

Analyst comments:

  • WTW +3% (initiated with a Overweight at JP Morgan)
  • ENBL +1% (upgraded to Equal Weight from Underweight at Barclays)
  • ALB +0.9% (upgraded to Buy from Hold at Vertical Research)

>>> US Early premarket gappers

Early premarket gappers

Gapping up:

  • NAKD +34.6%, RH +21.5%, PLAY +13.6%, BLDP +11.5%, LE +6.4%, KMG +5.9%, I +2.6%, BZUN +2.3%, AEIS +2.1%, FAST +1.9%, TWTR +1.9%, ENBL +1.7%, WTW +1.3%, CNHI +1.3%, MGIC +1.2%, SQ +1.2%, SOGO +1.1%

Gapping down:

  • JCAP -7.1%, HTGC -3.2%, NXPI -1.5%, BHP -1.3%, GFI -1.3%, MT -1%, BCS -1%, BBL -1%, RIO -0.6%, GDX -0.5%, GOLD -0.5%